{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000040","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-06-12T20:06:58+00:00","discovered_at":"2026-06-12T20:09:00.201532+00:00","generated_at":"2026-06-12T20:20:58.696278+00:00","sec_items":["3.02","3.03","5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance","bullets":["Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).","After exchange, 4,085.379 Series C shares remain outstanding.","Amended employment agreements for CEO Neil, CFO Sullivan, CMO Doyle, and CBO Boyd, changing severance and change-in-control terms.","CEO Neil gets 18-month base salary severance (others 12 months); on change-in-control termination, 1.5x base + 1x target bonus (others 1x/1x).","Pre-amendment options vest fully on qualifying termination; exercise period extended to 12 months for CEO/CFO, 6 months for CMO/CBO."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000040","json":"https://secwatch.observer/filing/0001534120-26-000040.json","markdown":"https://secwatch.observer/filing/0001534120-26-000040.md","text":"https://secwatch.observer/filing/0001534120-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/0001534120-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/avtx-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:20:58.696278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5dc58e815c3f5cda20465ed5de241fe96b82c27","claim":"Avalo Therapeutics, Inc. issued 4,294.675 shares of preferred stock to an accredited investor.","evidence_excerpt":"On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per share (the “Series C-1 Preferred Stock”), such exchange, the “Exchange”.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/0001534120-26-000040-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"4,294.675 shares"},{"label":"Purchaser","value":"an accredited investor"}],"fact_type":"equity_issuance"},{"claim_id":"818a1bc68707094c8ce7f962b3663195886c816d","claim":"Avalo Therapeutics, Inc.: Filed Certificate of Designation to designate Series C-1 Preferred Stock (effective 2026-06-11).","evidence_excerpt":"On June 11, 2026, in connection with the Exchange, the Company filed a Certificate of Designation to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Designation”), with the Secretary of State of the State of Delaware for the purpose of designating the Series C-1 Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/0001534120-26-000040-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}